 |
|
Stem cell transplants improve recovery in animal models for stroke, cerebral palsy
April 10, 2006A single dose of adult donor stem cells given to animals that have neurological damage similar to that experienced by adults with a stroke or newborns with cerebral palsy can significantly enhance recovery from these types of injuries, researchers say.
Using a commonly utilized animal model for stroke, researchers administered a dose of 200,000-400,000 human stem cells into the brain of animals that had experienced significant loss of mobility and other functions. The stem cells used in the study were a recently discovered stem cell type, referred to as multipotent adult progenitor cells, or MAPCs.
Treated animals experienced at least 25 percent greater improvement in motor and neurological performance than controls, said Dr. Cesario V. Borlongan, neuroscientist at the Medical College of Georgia and the Veterans Affairs Medical Center in Augusta.
The findings are being presented April 7 during the 58th annual meeting of the American Academy of Neurology in San Diego.
In humans, the findings hopefully will translate to incremental but important recovery advances, said Dr. David Hess, adult stroke specialist, chair of the MCG Department of Neurology and a study co-author. "The single largest cause of disability among adults in ths U.S. is stroke," said Dr. Hess. "It's a huge public health problem in the world." He hopes one day stem cell therapy, along with aggressive physical therapy and possibly tPA can work synergistically to reduce that disability.
"These are not going to be cures, but this level of recovery is significant, and could help get somebody out of a bed and into a wheelchair or out of a wheelchair to walking with a cane or from a cane to walking unassisted. If somebody can go from a wheelchair to a cane that is a big improvement, that is how we look at it," Dr. Hess said.
Adult animals were tested across a range of standardized tasks both before and after undergoing the surgically induced stroke, and measurements were made of their performance. Following the stroke, both control animals and those that received a single injection of stem cells were evaluated for a period of up to 2 months. Improvements in stem cell treated animals included enhanced performance across the range of tests, which examined strength, balance, agility and fine motor skills, and also included greater recovery of injured tissue.
"A single dose of the cells produce robust behavioral recovery at an early period post-transplantation and the recovery was durable, lasting up to two months, which was the entire length of this study," Dr. Borlongan said. "Furthermore, animals continued to show improvement over time." In the newborn model of ischemic injury, enhanced recovery was found within two weeks.
Even though less than 1 percent of the transplanted cells were present two months later, animals receiving treatment developed new neurons, apparently formed from endogenous stem cells. "The mechanism that we are putting forward is these donor cells are secreting nourishing trophic factors that are helping the host brain cells survive and stimulating stem cells from the host to multiply," Dr. Borlongan said.
To help mimic potential clinical scenarios for stroke victims, transplants were performed seven days after the initial injury. Currently, ischemic stroke patients may be treated with tPA, the only FDA-approved stroke treatment available, but must receive treatment within three hours from the time the stroke initially occurs. As a result, 95-97 percent of ischemic stroke victims never receive treatment with tPA.
In the adult stroke model, MCG researchers found giving stem cells increased the number of injured cells that survived in the area just outside the area of greatest damage, also referred to as the ischemic core, by 5-20 percent.
"Up to this point, all the treatment approaches, including transplantation and tPA, cannot get rid of that ischemic core," Dr. Borlongan said. "But outside of that core there is a lining, what we call the penumbra, and that penumbra, if you do not treat it over time, becomes part of the core. We are showing, that even one week after a stroke, we are able to increase the number of cells surviving along that penumbra and that is how we feel it is producing significant recovery, by rescuing cells within the penumbra."
Animals in the model of cerebral palsy, a condition caused by an ischemic injury similar to stroke but occurring before or during birth, also experienced at least a 25 percent improvement over controls. Rodent stem cells were used in this model, a larger percent of donated cells survived and within two weeks matured into neurons in the young, more pliable brains, Dr. Borlongan said. Also, close donor matching seemed unnecessary. Unmatched transplants, from the same species, and gentically identical transplants yielded essentially equal results.
Athersys, Inc., a Cleveland-based biopharmaceutical company pursuing cell therapy programs in cardiovascular disease, stroke, cancer and other diseases, funded the research in which previously frozen human or rodent multipotent adult progenitor cells, which the company calls MultiStem™, were thawed and injected directly into the brain.
Researchers believe that MultiStem™ cells are able to deliver a therapeutic benefit in multiple ways, for example by producing factors that limit tissue damage and stimulate repair, according to Dr. Gil Van Bokkelen, the company's chairman and chief executive officer. In addition, MultiStem™ cells can safely mature into a broad range of cell types and can be produced on a large scale, something which should ease the move toward clinical studies and eventual clinical use. "Given the number of stroke victims each year, it would be a big step forward if a safe and effective stem cell therapy could be produced, conveniently stored, and efficiently delivered on a widespread basis. We believe that we can achieve that with MultiStem™," commented Dr. Van Bokkelen.
In extensive animal testing, the mature stem cells have been shown to be safe, and do not form tumors or other abnormal tissue, a potential problem seen with embryonic stem cells. Furthermore, MultiStem™ cells generally do not require the close genetic matching between donor and recipient that is needed for a bone marrow or conventional stem cell transplant, according to company executives.
Another advantage is that use of immunosuppressive drugs does not appear to be required, in contrast to other types of stem cell treatment. Animals that received MultiStem™ without immunosuppression of any kind did just as well as animals that received MultiStem™ treatment along with daily doses of Cyclosporine A, a drug typically given to transplant recipients to prevent rejection. Such drugs can cause undesired side effects, and may be problematic if administered to patients for long periods of time. These results are consistent with those seen in other models, such as using MultiStem™ to treat damage caused by heart attacks, company officials say.
Although they have not specifically looked at whether stem cell therapy might be useful months after an ischemic event, MCG researchers and company scientists believe early therapy likely will be the most successful.
The researchers already are working with the Food and Drug Administration with the goal of beginning clinical trials within the next few years.
In preparation for potential clinical use, the researchers are pursuing transplants in larger animal models and studying how MultiStem™ cells work in living human brain tissue housed at the MCG Human Brain Bank, directed by Dr. Sergei Kirov.
"Number one is safety," said Dr. Borlongan. "We are moving more aggressively into carrying this into the clinic but, at the same time, we are going to be very cautious and thorough in monitoring for any safety issues."
Researchers also are working toward delivering the stem cells intravenously, an approach they believe will work because the cells naturally migrate to an injury site.
Other co-authors include Dr. James E. Carroll, chief of the Section of Pediatric Neurology; Dr. Lin Xu, MCG research scientist; Drs. Noriyuki Matsaukawa, Guolong Yu, Takao Yasuhara and Koichi Hara, MCG postdoctoral fellows; and Athersys scientists Robert W. Mays, and Robert J. Deans.
Medical College of Georgia
The findings are being presented April 7 during the 58th annual meeting of the American Academy of Neurology in San Diego.
In humans, the findings hopefully will translate to incremental but important recovery advances, said Dr. David Hess, adult stroke specialist, chair of the MCG Department of Neurology and a study co-author. "The single largest cause of disability among adults in ths U.S. is stroke," said Dr. Hess. "It's a huge public health problem in the world." He hopes one day stem cell therapy, along with aggressive physical therapy and possibly tPA can work synergistically to reduce that disability.
"These are not going to be cures, but this level of recovery is significant, and could help get somebody out of a bed and into a wheelchair or out of a wheelchair to walking with a cane or from a cane to walking unassisted. If somebody can go from a wheelchair to a cane that is a big improvement, that is how we look at it," Dr. Hess said.
Adult animals were tested across a range of standardized tasks both before and after undergoing the surgically induced stroke, and measurements were made of their performance. Following the stroke, both control animals and those that received a single injection of stem cells were evaluated for a period of up to 2 months. Improvements in stem cell treated animals included enhanced performance across the range of tests, which examined strength, balance, agility and fine motor skills, and also included greater recovery of injured tissue.
"A single dose of the cells produce robust behavioral recovery at an early period post-transplantation and the recovery was durable, lasting up to two months, which was the entire length of this study," Dr. Borlongan said. "Furthermore, animals continued to show improvement over time." In the newborn model of ischemic injury, enhanced recovery was found within two weeks.
Even though less than 1 percent of the transplanted cells were present two months later, animals receiving treatment developed new neurons, apparently formed from endogenous stem cells. "The mechanism that we are putting forward is these donor cells are secreting nourishing trophic factors that are helping the host brain cells survive and stimulating stem cells from the host to multiply," Dr. Borlongan said.
To help mimic potential clinical scenarios for stroke victims, transplants were performed seven days after the initial injury. Currently, ischemic stroke patients may be treated with tPA, the only FDA-approved stroke treatment available, but must receive treatment within three hours from the time the stroke initially occurs. As a result, 95-97 percent of ischemic stroke victims never receive treatment with tPA.
In the adult stroke model, MCG researchers found giving stem cells increased the number of injured cells that survived in the area just outside the area of greatest damage, also referred to as the ischemic core, by 5-20 percent.
"Up to this point, all the treatment approaches, including transplantation and tPA, cannot get rid of that ischemic core," Dr. Borlongan said. "But outside of that core there is a lining, what we call the penumbra, and that penumbra, if you do not treat it over time, becomes part of the core. We are showing, that even one week after a stroke, we are able to increase the number of cells surviving along that penumbra and that is how we feel it is producing significant recovery, by rescuing cells within the penumbra."
Animals in the model of cerebral palsy, a condition caused by an ischemic injury similar to stroke but occurring before or during birth, also experienced at least a 25 percent improvement over controls. Rodent stem cells were used in this model, a larger percent of donated cells survived and within two weeks matured into neurons in the young, more pliable brains, Dr. Borlongan said. Also, close donor matching seemed unnecessary. Unmatched transplants, from the same species, and gentically identical transplants yielded essentially equal results.
Athersys, Inc., a Cleveland-based biopharmaceutical company pursuing cell therapy programs in cardiovascular disease, stroke, cancer and other diseases, funded the research in which previously frozen human or rodent multipotent adult progenitor cells, which the company calls MultiStem™, were thawed and injected directly into the brain.
Researchers believe that MultiStem™ cells are able to deliver a therapeutic benefit in multiple ways, for example by producing factors that limit tissue damage and stimulate repair, according to Dr. Gil Van Bokkelen, the company's chairman and chief executive officer. In addition, MultiStem™ cells can safely mature into a broad range of cell types and can be produced on a large scale, something which should ease the move toward clinical studies and eventual clinical use. "Given the number of stroke victims each year, it would be a big step forward if a safe and effective stem cell therapy could be produced, conveniently stored, and efficiently delivered on a widespread basis. We believe that we can achieve that with MultiStem™," commented Dr. Van Bokkelen.
In extensive animal testing, the mature stem cells have been shown to be safe, and do not form tumors or other abnormal tissue, a potential problem seen with embryonic stem cells. Furthermore, MultiStem™ cells generally do not require the close genetic matching between donor and recipient that is needed for a bone marrow or conventional stem cell transplant, according to company executives.
Another advantage is that use of immunosuppressive drugs does not appear to be required, in contrast to other types of stem cell treatment. Animals that received MultiStem™ without immunosuppression of any kind did just as well as animals that received MultiStem™ treatment along with daily doses of Cyclosporine A, a drug typically given to transplant recipients to prevent rejection. Such drugs can cause undesired side effects, and may be problematic if administered to patients for long periods of time. These results are consistent with those seen in other models, such as using MultiStem™ to treat damage caused by heart attacks, company officials say.
Although they have not specifically looked at whether stem cell therapy might be useful months after an ischemic event, MCG researchers and company scientists believe early therapy likely will be the most successful.
The researchers already are working with the Food and Drug Administration with the goal of beginning clinical trials within the next few years.
In preparation for potential clinical use, the researchers are pursuing transplants in larger animal models and studying how MultiStem™ cells work in living human brain tissue housed at the MCG Human Brain Bank, directed by Dr. Sergei Kirov.
"Number one is safety," said Dr. Borlongan. "We are moving more aggressively into carrying this into the clinic but, at the same time, we are going to be very cautious and thorough in monitoring for any safety issues."
Researchers also are working toward delivering the stem cells intravenously, an approach they believe will work because the cells naturally migrate to an injury site.
Other co-authors include Dr. James E. Carroll, chief of the Section of Pediatric Neurology; Dr. Lin Xu, MCG research scientist; Drs. Noriyuki Matsaukawa, Guolong Yu, Takao Yasuhara and Koichi Hara, MCG postdoctoral fellows; and Athersys scientists Robert W. Mays, and Robert J. Deans.
Medical College of Georgia
Cerebral Palsy Current Events and Cerebral Palsy News RSSResearchers find aggressive phototherapy can improve neurodevelopmental outcomes in some preemies
Researchers at The University of Texas Medical School at Houston say the use of aggressive phototherapy reduces the odds that tiny premature infants will develop neurodevelopmental impairment such as cerebral palsy, blindness, deafness or physical or mental challenges.
Methylmercury warning
Recent studies hint that exposure to the toxic chemicals, such as methylmercury can cause harm at levels previously considered safe.
World-first to predict premature birth
Australian researchers and a pathology company have joined forces to develop a world-first computerised system which may reveal a way to predict premature birth with greater accuracy.
Common treatment to delay labor decreases preterm infants' risk for cerebral palsy
Intravenous magnesium sulfate supplementation before preterm delivery cuts the risk for handicapping cerebral palsy in half, according to research led by University of Alabama at Birmingham (UAB) obstetrician Dwight Rouse, M.D., and published in the Aug. 28 issue of The New England Journal of Medicine.
Researchers find differences in swallowing mechanism of Rett syndrome patients
Researchers at Wake Forest University Baptist Medical Center have found that the reflux and swallowing problems that are common symptoms in patients with Rett syndrome and other neurological impairments, may be caused by a different mechanism than they are in healthy individuals.
Preterm birth contributes to growing number of infant deaths
Babies born too soon and too small accounted for a growing proportion of infant deaths, according to new statistics released today from the National Center for Health Statistics, (NCHS).
New research on pre-eclampsia in mice may have important implications for humans
In a new March of Dimes-funded study of pre-eclampsia, a serious and potentially deadly disorder that affects about 5 percent of pregnancies, researchers have found results in mice that may have important implications for diagnosis and treatment in humans.
IVF does not increase risk of developmental disorders in children
Couples who need IVF in order to become pregnant can be reassured that this will not lead to developmental problems in early infancy.
Toys and technology for rehabilitation in cerebral palsy patients
What began as a college course project to design therapeutic toys has resulted in the first toys of their kind, designed as therapy for children with cerebral palsy (CP).
Resuscitation technique after brain injury may do more harm than good
The current standard practice of giving infants and children 100 percent oxygen to prevent brain damage caused by oxygen deprivation may actually inflict additional harm, researchers at UT Southwestern Medical Center have found.
More Cerebral Palsy Current Events and Cerebral Palsy News Articles
 | Teaching Motor Skills to Children With Cerebral Palsy And Similar Movement Disorders: A Guide for Parents And Professionals by Sieglinde Martin (2007 Independent Publisher Award Bronze Medalist, Health/Medicine/Nutrition category) All children with cerebral palsy and other conditions that result in gross motor delays need help and reinforcement to learn basic motor skills, usually with assistance from a physical therapist. Because the degree of developmental delay varies greatly from child to child, a thorough motor evaluation is an... |
 | Children With Cerebral Palsy: A Parents' Guide The future is brighter then ever for children with cerebral palsy -- the most common developmental disability among young people today. With advances in medicine, early intervention, and therapy, these children can maximise their potential and lead healthy, rewarding lives. But perhaps the most important influence of all comes from parents who provide constant support and encouragement. This is... |
 | My Perfect Son Has Cerebral Palsy: A Mother's Guide of Helpful Hints by Marie A. Kennedy |
 | Children With Cerebral Palsy: A Manual for Therapists, Parents and Community Workers (Children with Cerebral Palsy: A Manual for Therapists, Parents,) ... Palsy: A Manual for Therapists, Parents,) by Archie Hinchcliffe This book is a practical guide to the effective treatment of cerebral palsy in children. It provides a set of principles by which to observe and analyze individual patients' problems and then plan treatment. With the help of this book, non-specialists working with children with cerebral palsy can make decisions and choose the appropriate therapeutic activities for each child. It includes examples... |
 | Cerebral Palsy: A Complete Guide for Caregiving (A Johns Hopkins Press Health Book) by Freeman Miller, Steven J. Bachrach When a child has a health problem, parents want answers. But when a child has cerebral palsy, the answers don't come quickly. A diagnosis of this complex group of chronic conditions affecting movement and coordination is difficult to make and is typically delayed until the child is eighteen months old. Although the condition may be mild or severe, even general predictions about long-term... |
 | Physical Therapy of Cerebral Palsy This book is a derivative of Dr. Miller’s well-regarded Cerebral Palsy and focuses on rehabilitation techniques. The book discusses the theory and techniques used by physical and occupational therapists, and also provides suggestions for implementing an Individual Education Plan. Tables and algorithms are included to help in the decision-making process for determining what treatment would be... |
 | Handling the Young Child with Cerebral Palsy at Home by Nancie R. Finnie Fundamental to the successful treatment of children with cerebral palsy is the cooperation of parents in home handling. The long-awaited new edition of this classic and popular text has been expanded and updated to include a wealth of new information for therapists, nurses, parents and... |
 | Nathan's Wish: A Story About Cerebral Palsy by Laurie Lears Nathan lives next door to Miss Sandy, a raptor rehabilitator. She’s very busy taking care of injured birds of prey, like owls and hawks. Nathan wishes he could help Miss Sandy with some of her chores, but he is confined to his wheelchair because of cerebral palsy. Then Fire, an owl with a broken wing, comes to Miss Sandy. Fire is desperate to fly and Nathan can’t wait for Fire to get her... |
 | Neonatal Encephalopathy and Cerebral Palsy: Defining the Pathogenesis & Pathophysiology : A Report by Ralph Adamo, Acog Explores fetal and neonatal neurologic injury and presents evidence that most cases of cerebral palsy result from multifactorial and unpreventable causes that occur during fetal development or in the newborn after... |
 | Hyperbaric Oxygenation for Cerebral Palsy and the Brain Injured Child: A Promising Treatment by Richard A. Neubauer This book is a complete guide for caregivers of children with cerebral palsy or traumatic brain injuries who are considering using hyperbaric oxygenation therapy. Written in a semi-scientific manner, the information should also be of value to physicians, researchers, and insurance providers seeking accurate and proven insight about the value of hyperbaric oxygenation therapy for... |
| © 2008 BrightSurf.com |